Grauer & Weil (GRAUWEIL)
CyclicalFairStock Score: 32/100 — RISKY
Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹67.39 |
| Market Cap | ₹3,055.54 Cr |
| P/E Ratio | 19.04 |
| ROCE | 23.34% |
| ROE | 16.38% |
| Dividend Yield | 0.74% |
| Profit Growth | -8.3% |
| Debt/Equity | 0.01 |
| Sales Growth | 17.9% |
| Promoter Holding | 69.03% |
| 52-Week Range | ₹49.7 — ₹88.87 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹23.81 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At ₹73.09, Grauer & Weil is being priced as if it has something special, but I see a commodity chemical business with a price-earnings ratio of 20.21 and a profit decline of 25.02%. The market cap is ₹2,834 Cr. Let me start with strengths: return on capital employed is 23.34%, return on equity is 16.38%, and debt/equity is 0.01. That is a solid financial base. Promoter holding of 69.03% suggests ownership is aligned, at least in structure. But a fine balance sheet cannot turn a price taker into a pricing-power franchise. In commodity chemicals, there is little moat; customers buy on price and availability. Sales grew only 5.76%, while profits fell sharply. That tells me growth is not converting into earnings. The Piotroski F-score of 4 out of 9 is a warning sign on financial quality. The PEG of 3.51 makes no sense for a business with negative profit growth; you are paying a rich multiple for deteriorating earnings. Book value is ₹18.55, so at ₹73.09 I am paying 3.94 times book. The FairStock score of 29/100 flags this as risky, and Graham would call that speculative. A ₹291 Cr quarter with ₹32 Cr net profit is decent on the surface, but one quarter does not change the trend. Dividend yield of 0.80% offers little compensation while I wait. This is a cyclical commodity-chemical company, not a stalwart. I do not need to own every business; I need to own understandable, growing earnings at a sensible price. Here, the earnings are going backward and the price is not. I would put this on the watchlist, not in the portfolio. For patient investors, wait for a better price, or for proof that the profit decline has reversed. Until then, caution is the right word.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer